(Q38569772)

4 September 2017

title

Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives (English)

1 reference

4 September 2017

0 references

1 reference

1 reference

2

1 reference

4 September 2017

author name string

Tiffanie Daisy Sugianto

series ordinal

1

1 reference

4 September 2017

language of work or name

English

0 references

publication date

18 August 2015

1 reference

Expert Opinion on Drug Delivery

4 September 2017

published in

1 reference

4 September 2017

volume

13

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

7-22

1 reference

Non-cystic fibrosis bronchiectasis

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhalation of macrolides: a novel approach to treatment of pulmonary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Aerosolized antibiotics for non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Delivery of antibiotics with polymeric particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled antimicrobial therapy - barriers to effective treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

British Thoracic Society guideline for non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Treatment adherence and health outcomes in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled antibiotics to treat lung infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

The PulmoSphere™ platform for pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled azithromycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Delivery strategies for sustained drug release in the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Liposomal formulations for inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

The bronchiectasis severity index. An international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Defining severity in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Research priorities in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled antibiotics for lower airway infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Aminoglycoside antibiotics induce bacterial biofilm formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

A novel microbiota stratification system predicts future exacerbations in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Lung clearance index in adults with non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Qualitative analysis of high-resolution CT scans in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

High azithromycin loading powders for inhalation and their in vivo evaluation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

NanoCipro encapsulation in monodisperse large porous PLGA microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Cospray dried antibiotics for dry powder lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Controlled release antibiotics for dry powder lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

A novel inhaled multi-pronged attack against respiratory bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Nebulized Colistin for Non–Cystic Fibrosis Bronchiectasis: Déjà Vu All Over Again?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.1078309

10.1517/17425247.2015.1078309

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference